Article Data

  • Views 569
  • Dowloads 114

Original Research

Open Access

Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women

  • Panteleimon Mnimatidis1,*,
  • Abraham Pouliakis2
  • George Valasoulis3
  • George Michail4
  • Aris Spathis2
  • Christine Cottaridi2
  • Niki Margari5
  • Maria Kyrgiou6,7
  • Maria Nasioutziki8
  • Alexandros Daponte9
  • Konstantinos Dinas8
  • Evangelos Paraskevaidis10
  • Ioannis Panayiotides2
  • Dimitrios-Dionysios Koutsouris1

1Biomedical Engineering Laboratory, National Technical University of Athens, Iroon Politechniou 9, 15780, Zografou, Athens, Greece

2Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, Rimini 1, 12464, Haidari, Athens, Greece

3Department of Obstetrics & Gynaecology, Health Center of Larisa, Roosevelt 4, 41222, Larisa, Greece

4Department of Obstetrics & Gynaecology, University Hospital of Patras, 26504, Rio, Patras, Greece

5Private Cytopathology Laboratory, Kifissias avenue 27A, 11523, Ampelokipi, Athens, Greece

6Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer, Imperial College, Hammersmith Campus, Du Cane Road, W12 0NN, London, Great Britain

7West London Gynaecological Cancer Centre, Queen Charlotte's and Chelsea - Hammersmith Hospital, Imperial Healthcare NHS Trust, Du Cane Road, W12 0HS, White City, London, Great Britain

82nd Department of Obstetrics & Gynecology and Molecular Clinical Cytology Laboratory, Hippokration Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642, Thessaloniki, Greece

9Department of Obstetrics & Gynaecology, University Hospital of Larisa, Mezourlo, 41110, Larisa, Greece

10Department of Obstetrics & Gynaecology, University Hospital of Ioannina, Leof. Stavrou Niarchou 1, 45500, Ioannina, Greece

DOI: 10.31083/j.ejgo.2020.04.5180 Vol.41,Issue 4,August 2020 pp.545-555

Submitted: 11 March 2018 Accepted: 05 June 2019

Published: 15 August 2020

*Corresponding Author(s): Panteleimon Mnimatidis E-mail: pmnimati@yahoo.gr

Abstract

Purpose of Investigation: Despite the general principle that persistent high risk human papillomavirus (hr-HPV) infection may progressively cause cervical cancer (CxCa), demographic aspects may still identify groups at high risk for HPV infection and consequently for precancerous lesions. The role of demographic parameters on cervical status, the diagnostic accuracy of cytology, HPV genotyping, and their possible combinations, were investigated in this study. Materials and Methods: 11,072 women from diverse locations across Greece participated in the study. Liquid Based Cytologic (LBC) assessment was followed, when necessary, by HPV-genotyping and histologic confirmation. Demographic characteristics were also assessed. Results: Life style parameters such as age, number of sexual partners, condom use, parity and marital status, education level, and combination of smoking/condom use, were significant factors for CIN2+ lesions (p < 0.05). For LSIL+ detection, cytology had maximum sensitivity: 96.90%, HPV-typing: 72.55% and co-testing: 98.97%, for HSIL+ detection: 98.49%, 92.22%, and 99.55% respectively. Conclusions: There are notable relationships between lifestyle, demographic details, and cervical status. Despite the differences in sensitivity and specificity levels, co-testing might offer some marginal improvement in the detection of particular pre-cancerous conditions.

Keywords

Cervical cancer; Biomarkers; Cervical cytology; Cervical intraepithelial neoplasia; HPV

Cite and Share

Panteleimon Mnimatidis,Abraham Pouliakis,George Valasoulis,George Michail,Aris Spathis,Christine Cottaridi,Niki Margari,Maria Kyrgiou,Maria Nasioutziki,Alexandros Daponte,Konstantinos Dinas,Evangelos Paraskevaidis,Ioannis Panayiotides,Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women. European Journal of Gynaecological Oncology. 2020. 41(4);545-555.

References

[1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[2] Papanicolaou G. (ed). New Cancer Diagnosis. 3rd Race Bettrment Conference. Battle Creek: 1928.

[3] Papanicolaou G., Traut H.: “The diagnostic value of vaginal smears in carcinoma of the uterus”. Am. J. Obst et.Gynecol., 1941, 42, 193.

[4] Diamantis A., Magiorkinis E., Koutselini H.: “50 years after the death of George Nicholas Papanicolaou (1883-1962): evaluation of his scientific work”. Acta Med. Hist. Adriat., 2014, 12, 181.

[5] Karakitsos P., Chrelias C., Pouliakis A., Koliopoulos G., Spathis A., Kyrgiou M., et al.: “Identification of women for referral to colposcopy by neural networks: a preliminary study based on LBC and molecular biomarkers”. J. Biomed. Biotechnol., 2012, 2012, 303192.

[6] Koliopoulos G., Valasoulis G., Zilakou E.: “An update review on HPV testing methods for cervical neoplasia”. Expert Opin. Med. Di- agn., 2009, 3, 123.

[7] Tsoumpou I., Valasoulis G., Founta C., Kyrgiou M., Nasioutziki M., Daponte A., et al.: “High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study”. Gynecol. Oncol., 2011, 121, 49.

[8] Paraskevaidis E., Arbyn M., Sotiriadis A., Diakomanolis E., Martin-Hirsch P., Koliopoulos G., et al.: “The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature”. Cancer Treat. Rev., 2004, 30, 205.

[9] Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., Dillner J.: “Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence”. Gynecol. Oncol., 2005, 99, S7.

[10] Valasoulis G., Stasinou S.M., Nasioutziki M., Athanasiou A., Zografou M., Spathis A., et al.: “Expression of HPV-related biomarkers and grade of cervical intraepithelial lesion at treatment”. Acta Obstet. Gynecol. Scand., 2014, 93, 194.

[11] Kyrgiou M., Valasoulis G., Founta C., Koliopoulos G., Karakitsos P., Nasioutziki M., et al.: “Clinical management of HPV-related disease of the lower genital tract”. Ann N Y Acad Sci, 2010, 1205, 57.

[12] Stiasny A., Kuhn C., Mayr D., Alexiou C., Janko C., Wiest I., et al.: “Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer”. Anticancer Res., 2016, 36, 3195.

[13] Lee B., Suh D.H., Kim K., No J.H., Kim Y.B.: “Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology”. Anticancer Res., 2015, 35, 4197.

[14] Stasinou S.M., Valasoulis G., Kyrgiou M., Malamou-Mitsi V., Bilirakis E., Pappa L., et al.: “Large loop excision of the transformation zone and cervical intraepithelial neoplasia: a 22-year experience”. Anticancer Res., 2012, 32, 4141.

[15] Paba P., Ascone C., Criscuolo A.A., Marcuccilli F., Ciccozzi M., Sesti F., et al.: “Human papillomavirus molecular testing in women with low grade cervical lesions: experience from an Italian hospital”. Anticancer Res., 2012, 32, 1253.

[16] Smits H.L., van Gemen B., Schukkink R., van der Velden J., Tjong A.H.S.P., Jebbink M.F., et al.: “Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts”. J. Virol. Methods, 1995, 54, 75.

[17] Stathopoulou V., Koliopoulos G., Zygouris D., Pappas A., Spathis A., Karakitsos P., et al.: “The diagnostic accuracy of E6 & 7 mRNA detection as a primary screening test for the detection of severe cer- vical lesions”. J. BUON., 2014, 19, 490.

[18] Koliopoulos G., Chrelias C., Pappas A., Makridima S., Kountouris E., Alepaki M., et al.: “The diagnostic accuracy of two methods for E6&7 mRNA detection in women with minor cytological abnormalities”. Acta Obstet. Gynecol. Scand., 2012, 91, 794.

[19] Kottaridi C., Tsiodras S., Spathis A., Chranioti A., Pappas A., Kas- sanos D., et al.: “Clinical performance of human papillomavirus E6, E7 mRNA flow cytometric assay compared to human papillomavirus DNA typing”. Anal. Quant. Cytol. Histol., 2011, 33, 305.

[20] Spathis A., Kottaridi C., Chranioti A., Meristoudis C., Chrelias C., Panayiotides I.G., et al.: “mRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clin- ics”. PLoS One, 2012, 7, e49205.

[21] Trope A., Sjoborg K., Eskild A., Cuschieri K., Eriksen T., Thoresen S., et al.: “Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia”. J. Clin. Microbiol., 2009, 47, 2458.

[22] Sorbye S.W., Fismen S., Gutteberg T., Mortensen E.S.: “Triage of women with minor cervical lesions: data suggesting a “test and treat” approach for HPV E6/E7 mRNA testing”. PLoS One, 2010, 5, e12724.

[23] Narimatsu R., Patterson B.K.: “High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry”. Am. J. Clin. Pathol., 2005, 123, 716.

[24] Coquillard G., Palao B., Patterson B.K.: “Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA”. Gynecol. Oncol., 2011, 120, 89.

[25] Kyrgiou M., Pouliakis A., Panayiotides J.G., Margari N., Bountris P., Valasoulis G., et al.: “Personalised management of women with cervical abnormalities using a clinical decision support scoring system”. Gynecol Oncol, 2016, 141, 29.

[26] Bountris P., Haritou M., Pouliakis A., Karakitsos P., Koutsouris D.: “A decision support system based on an ensemble of random forests for improving the management of women with abnormal findings at cervical cancer screening”. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2015, 2015, 8151.

[27] Pouliakis A., Karakitsou E., Chrelias C., Pappas A., Panayiotides I., Valasoulis G., et al.: “The Application of Classification and Regression Trees for the Triage of Women for Referral to Colposcopy and the Estimation of Risk for Cervical Intraepithelial Neoplasia: A Study Based on 1625 Cases with Incomplete Data from Molecular Tests”. Biomed. Res. Int., 2015, 2015, 914740.

[28] Nieh S., Chen S.F., Chu T.Y., Lai H.C., Lin Y.S., Fu E., et al.: “Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undeter- mined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies”. Gynecol. Oncol., 2005, 97, 35.

[29] Nasioutziki M., Daniilidis A., Dinas K., Kyrgiou M., Valasoulis G., Loufopoulos P.D., et al.: “The evaluation of p16INK4a immuno-expression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples”. Int. J. Gynecol. Cancer, 2011, 21, 79.

[30] Valasoulis G., Tsoumpou I., Founta C., Kyrgiou M., Dalkalitsis N., Nasioutziki M., et al.: “The role of p16(INK4a) immunostaining in the risk assessment of women with LSIL cytology: a prospective pragmatic study”. Eur. J. Gynaecol. Oncol., 2011, 32, 150.

[31] Reuschenbach M., Wentzensen N., Dijkstra M.G., von Knebel Doeberitz M., Arbyn M.: “p16INK4a immunohistochemistry in cervical biopsy specimens: A systematic review and meta-analysis of the interobserver agreement”. Am. J. Clin. Pathol., 2014, 142, 767.

[32] Valasoulis G., Stasinou S.M., Nasioutziki M., Athanasiou A., Zo- grafou M., Spathis A., et al.: “Expression of HPV-related biomarkers and grade of cervical intraepithelial lesion at treatment”. Acta Obstet Gynecol Scand, 2013.

[33] Lima K.M.G., Gajjar K., Valasoulis G., Nasioutziki M., Kyrgiou M., Karakitsos P., et al.: “Classification of cervical cytology for human papilloma virus (HPV) infection using biospectroscopy and variable selection techniques”. Analytical Methods, 2014, 6, 9643.

[34] Kottaridi C., Kyrgiou M., Pouliakis A., Magkana M., Aga E., Spathis A., et al.: “Quantitative Measurement of L1 Human Papillomavirus Type 16 Methylation for the Prediction of Preinvasive and Invasive Cervical Disease”. J. Infect. Dis., 2017, 215, 764.

[35] Amaro-Filho S.M., Pereira Chaves C.B., Felix S.P., Basto D.L., de Almeida L.M., Moreira M.A.M.: “HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer”. Papillomavirus Res., 2018, 5, 172.

[36] Clarke M.A., Gradissimo A., Schiffman M., Lam J., Sollecito C.C., Fetterman B., et al.: “Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women”. Clin. Cancer Res., 2018, 24, 2194.

[37] Gocze K., Gombos K., Juhasz K., Kovacs K., Kajtar B., Benczik M., et al.: “Unique microRNA expression profiles in cervical cancer”. Anticancer Res., 2013, 33, 2561.

[38] Babion I., Snoek B.C., Novianti P.W., Jaspers A., van Trommel N., Heideman D.A.M., et al.: “Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study”. Clin. Epigenetics, 2018, 10, 76.

[39] Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al.: “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer”. N. Engl. J. Med., 2007, 357, 1579.

[40] Mathew A., George P.S.: “Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix— worldwide”. Asian Pac. J. Cancer Prev., 2009, 10, 645.

[41] Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al.: “Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries”. Vaccine, 2008, 26, K29.

[42] Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al.: “Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening”. J. Natl. Cancer Inst., 2009, 101, 88.

[43] Benevolo M., Vocaturo A., Caraceni D., French D., Rosini S., Zappacosta R., et al.: “Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test”. J. Clin. Microbiol., 2011, 49, 2643.

[44] Cuschieri K., Wentzensen N.: “Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 2536.

[45] Carozzi F.M.: “Combined analysis of HPV DNA and p16INK4a expression to predict prognosis in ASCUS and LSIL pap smears”. Coll. Antropol., 2007, 31, 103.

[46] Denton K.J., Bergeron C., Klement P., Trunk M.J., Keller T., Ridder R.: “The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results”. Am. J. Clin. Pathol., 2010, 134, 12.

[47] Gajjar K., Ahmadzai A.A., Valasoulis G., Trevisan J., Founta C., Nasioutziki M., et al.: “Histology verification demonstrates that biospectroscopy analysis of cervical cytology identifies underlying disease more accurately than conventional screening: removing the confounder of discordance”. PLoS One, 2014, 9, e82416.

[48] Purandare N.C., Trevisan J., Patel, II, Gajjar K., Mitchell A.L., Theophilou G., et al.: “Exploiting biospectroscopy as a novel screening tool for cervical cancer: towards a framework to validate its accuracy in a routine clinical setting”. Bioanalysis, 2013, 5, 2697.

[49] Arbyn M., Xu L., Verdoodt F., Cuzick J., Szarewski A., Belinson J.L., et al.: “Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis”. Ann Intern Med, 2017, 166, 118.

[50] Xu L., Verdoodt F., Wentzensen N., Bergeron C., Arbyn M.: “Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer”. Cancer Cytopathol., 2016, 124, 261.

[51] Verdoodt F., Szarewski A., Halfon P., Cuschieri K., Arbyn M.: “Triage of women with minor abnormal cervical cytology: meta- analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types”. Cancer Cytopathol., 2013, 121, 675.

[52] Van S.N., Khac M.N., Dimberg J., Matussek A., Henningsson A.J.: “Prevalence of Cervical Infection and Genotype Distribution of Human Papilloma Virus Among Females in Da Nang, Vietnam”. Anticancer Res., 2017, 37, 1243.

[53] Henry M.R.: “The Bethesda System 2001: an update of new termi- nology for gynecologic cytology”. Clin. Lab. Med., 2003, 23, 585.

[54] Smith J.H.: “Bethesda 2001”. Cytopathology, 2002, 13, 4.

[55] Gomez-Roman J.J., Echevarria C., Salas S., Gonzalez-Moran M.A., Perez-Mies B., Garcia-Higuera I., et al.: “A type-specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions”. APMIS, 2009, 117, 22.

[56] Paraskevaidis E., Davidson E.J., Koliopoulos G., Alamanos Y., Lolis E., Martin-Hirsch P.: “Bleeding after loop electrosurgical excision procedure performed in either the follicular or luteal phase of the menstrual cycle: a randomized trial”. Obstet. Gynecol., 2002, 99, 997.

[57] Giannopoulos T., Butler-Manuel S., Tailor A., Demetriou E., Daborn L.: “Prevalence of high-grade CIN following mild dyskaryotic smears in different age groups”. Cytopathology, 2005, 16, 277.

[58] Chan J.K., Monk B.J., Brewer C., Keefe K.A., Osann K., McMeekin S., et al.: “HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3”. Br. J. Cancer, 2003, 89, 1062.

[59] Thomas I., Wright G., Ward B.: “The effect of condom use on cer- vical intraepithelial neoplasia grade I (CIN I)”. Aust. N. Z. J. Obstet. Gynaecol., 1990, 30, 236.

[60] Lam J.U., Rebolj M., Dugue P.A., Bonde J., von Euler-Chelpin M., Lynge E.: “Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies”. J. Med. Screen., 2014, 21, 38.

[61] Winer R.L., Hughes J.P., Feng Q., O’Reilly S., Kiviat N.B., Holmes K.K., et al.: “Condom use and the risk of genital human papillomavirus infection in young women”. N. Engl. J. Med., 2006, 354, 2645.

[62] Chih H.J., Lee A.H., Colville L., Xu D., Binns C.W.: “Condom and oral contraceptive use and risk of cervical intraepithelial neoplasia in Australian women”. J. Gynecol. Oncol., 2014, 25, 183.

[63] Valasoulis G., Koliopoulos G., Founta C., Kyrgiou M., Tsoumpou I., Valari O., et al.: “Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia”. Gynecol. Oncol., 2011, 121, 43.

[64] Valasoulis G.: “Effect of condom use after CIN treatment on HPV status: a randomised controlled trial” University of Ioannina, 2014.

[65] Jensen K.E., Schmiedel S., Norrild B., Frederiksen K., Iftner T., Kjaer S.K.: “Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up”. Br. J. Cancer, 2012, 108, 234.

[66] Jensen K.E., Schmiedel S., Norrild B., Frederiksen K., Iftner T., Kjaer S.K.: “Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up”. Br. J. Cancer, 2013, 108, 234.

[67] Ngaon L.T., Yoshimura T.: “Parity and Illiteracy as Risk Factors of Cervical Cancers in Viet Nam”. Asian Pac. J. Cancer Prev., 2001, 2, 203.

[68] de Graaff J., Stolte L.A., Janssens J.: “Marriage and childbearing in relation to cervical cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1977, 7, 307.

[69] Damiani G., Basso D., Acampora A., Bianchi C.B., Silvestrini G., Frisicale E.M., et al.: “The impact of level of education on adherence to breast and cervical cancer screening: Evidence from a systematic review and meta-analysis”. Prev. Med., 2015, 81, 281.

[70] Franceschi S., Plummer M., Clifford G., de Sanjose S., Bosch X., Herrero R., et al.: “Differences in the risk of cervical cancer and human papillomavirus infection by education level”. Br. J. Cancer, 2009, 101, 865.

[71] Chatzistamatiou K., Moysiadis T., Vryzas D., Chatzaki E., Kaufmann A.M., Koch I., et al.: “Cigarette Smoking Promotes Infection of Cervical Cells by High-Risk Human Papillomaviruses, but not Subsequent E7 Oncoprotein Expression”. Int. J. Mol. Sci., 2018, 19.

[72] Cervical Cancer Incidence and Mortality Worldwide in 2008 S.: “GLOBOCAN (IARC)”. Section of cancer information, 2008 7/7/2011.

[73] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics, 2012”. CA Cancer J. Clin., 2015, 65, 87.

[74] Tsakiroglou M., Bakalis M., Valasoulis G., Paschopoulos M., Koliopoulos G., Paraskevaidis E.: “Women’s knowledge and utiliza- tion of gynecological cancer prevention services in the Northwest of Greece”. Eur. J. Gynaecol. Oncol., 2011, 32, 178.

[75] Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., et al.: “Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe”. Int. J. Cancer, 2013, 132, 854.

[76] Lyons Y.A., Kamat A.A., Zhou H., Mody D.R., Schwartz M.R., Hobday C., et al.: “Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpre- tation of LSIL”. Cancer Cytopathol., 2015, 123, 435

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top